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ity and relevance of single measurements taken at differentPretreatment blood pressure reliably predicts progression of
times after treatment administration are questionable.chronic nephropathies.
Background. Random, nontimed blood pressure (BP) mea-
surements in the outpatient clinic may fail to provide reliable
information on actual daily BP control in renal patients on
Progressive renal function deterioration occurs in mostchronic antihypertensive therapy.
forms of chronic nephropathy [1]. A recognized majorMethods. In a cohort of 163 patients with proteinuric chronic
nephropathies followed prospectively with repeated BP and determinant of renal injury in these circumstances is
glomerular filtration rate (GFR) measurements, we compared arterial hypertension: the higher the levels of arterial
baseline and follow-up pretreatment, morning (“trough,” mea- blood pressure (BP), the greater the risk of a given pa-sured by standard procedures, and “0 minutes,” measured by
tient to develop renal failure in the long term [2, 3].an automatic device) and post-treatment (120 minutes) mea-
On the other hand, many clinical studies are availablesurements, with BP monitored up to 600 minutes after treat-
ment administration. We then evaluated which BP value most indicating that BP reduction is protective [reviewed in
reliably predicted GFR decline (DGFR) and progression to 4]. In most intervention trials aimed at evaluating the
end-stage renal failure (ESRF) over a median (interquartile effect of different antihypertensive regimens on diseaserange) follow-up of 20 (9 to 25) months.
progression to renal failure, reported values of arterialResults. GFR decline was more reliably predicted by systolic
BP were random measurements in outpatient clinics,as compared with diastolic BP and by pretreatment as com-
pared to post-treatment BP, regardless of the timing and which may lead to different results depending on the
method of measurement, respectively. In particular, at the 120- time BP is measured [5–8]. Actually, in some studies,
minute baseline and follow-up measurements, systolic BP had
BP was measured in the morning just before the adminis-no predictive value in patients with less severe renal insuffi-
tration of antihypertensive medication, when the resid-ciency and baseline diastolic BP, regardless of the level of renal
dysfunction. The BP predictive value was remarkably higher ual effect of treatment is minimal (“trough” BP) [9–11].
in ramipril than in conventionally treated patients. All follow- In a few others, the BP was measured shortly after the
up—but no baseline—measurements reliably predicted the risk administration of the antihypertensive treatment, con-
of ESRF in the entire study group.
ceivably when the medication has achieved the peakConclusions. In patients with progressive chronic nephropa-
effect [12]. However, most of the studies did not reportthies, systolic BP and pretreatment morning BP measurements
are the most reliable predictors of disease outcome and may the timing of BP measurements [5–8], which renders data
serve to guide antihypertensive therapy in routine clinical activ- interpretation even more difficult. One also has to take
ities and in prospective controlled trials, particularly in patients into account that random measurements in the outpa-on angiotensin-converting enzyme inhibitor therapy. Reliabil-
tient clinic do not distinguish sustained hypertension
from “white-coat hypertension” and, even more impor-
1 Gruppo Italiano di Studi Epidemiologici in Nefrologia tant, fail to provide information on daily response to
medication [13].
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test the hypothesis that protein traffic and its reduction Study design
by an ACE inhibitor influenced renal disease progression Following screening evaluation, all eligible patients
[9]. In all patients, “trough” BP was measured by a stan- entered a one-month, single-blind, placebo run-in phase.
dard sphygmomanometer in the morning, after five min- Patients were given one placebo capsule daily and were
utes of rest in the sitting position, and mean values of asked to return to the hospital after 15 and 30 days for
three consecutive measurements two minutes apart were the measurement of BP, creatinine clearance, and 24-
recorded. A subgroup of patients, however, during the hour urinary protein excretion, and to evaluate routine
occasion of glomerular filtration rate (GFR) measure- hematochemistry, complete blood cell count, and tablet
compliance. On day 15, the GFR was determined byments, had their BP also measured by an automatic de-
the plasma clearance measurement of unlabeled iohexolvice from the time the “trough” value was taken (“time
[14]. Patients with a creatinine clearance of 20 to 70 mL/0”) up to 10 hours after treatment administration. This
min/1.73 m2, urinary protein excretion $1 g/24 hours,allowed a comparison of the BP values taken at different
serum potassium concentration 3.5 to 5 mEq/L, and tab-times—regardless of the adopted method of measure-
let compliance .80% (means of the determinations atment—and to evaluate which of them more reliably pre-
day 15 and at day 30) entered the randomized double-dicted disease progression and response to treatment.
blind phase of the study. According to mean urinaryBy this approach, we also had the unique opportunity
protein excretion at day 15 and at day 30, patients wereto monitor and compare BP response to ACE and non-
stratified into two strata: stratum 1:.1 and ,3 g/24 hoursACE inhibitor therapy in a large cohort of patients with
and stratum 2:$3 g/24 hours.chronic progressive nephropathies and different degrees
At the end of the placebo run-in phase, in each center,of renal dysfunction. The results of these post hoc analy-
the patients were randomly assigned to receive 1.25 mgses form the basis of this report.
capsules of ramipril or placebo (identical appearance)
on a 1:1 basis within each stratum. The dose of the study
drugs was titrated upward every two weeks to 2.5 or 5METHODS
mg/day of ramipril or placebo until diastolic BP wasThe design of the REIN study has been described in
reduced below 90 mm Hg. Antihypertensive agents (butdetail elsewhere [9–11]. The protocol was approved by
not ACE inhibitors) were introduced, and their dosesthe ethical committee and by the institutional review
were adjusted whenever appropriate to achieve andboard of the 14 hospitals involved. Every patient gave
maintain diastolic BP ,90 mm Hg. In patients alreadywritten informed consent. The primary study objectives
treated with antihypertensive agents, the dose of thewere to assess the effects of treatment with ramipril
study drugs was titrated upward, and the dose of otheron DGFR and time to end-stage renal failure (ESRF).
antihypertensives progressively reduced to avoid symp-Secondary objectives were to assess the long-term effects
tomatic hypotension. In each patient, the general goalof treatment with ramipril on the degree of proteinuria
was to adjust the dose of the study drugs in order to
and incidence of major cardiovascular complications,
achieve and maintain the target BP with the minimum
and the total and cardiovascular mortality rates. dose of concomitant antihypertensive agents. ACE in-
hibitors or angiotensin II receptor antagonists could notPatients and definitions
be added to the study drugs throughout the whole study
Study participants were normotensive or hypertensive period.
patients of both sexes, between 18 and 70 years old, with All of the patients were recommended to limit their
chronic nephropathy and persistent proteinuria, who had sodium intake and to eat 0.6 to 0.8 g/kg/day of protein
not received ACE inhibition therapy for at least two per kilogram of body weight per day. No change in the
months or any treatment with corticosteroids, nonster- diet was then introduced during the study. Dietary com-
oidal anti-inflammatory drugs (NSAIDs), or immuno- pliance was assessed by evaluating 24-hour urinary so-
suppressive drugs for at least six months. Chronic ne- dium and urea excretion.
phropathy was defined as creatinine clearance in the At randomization, every month during the first three
range of 20 to 70 mL/min/1.73 m2 with a variation of months, and every three months thereafter, each patient
less than 30% in the three months prior to screening was examined by a physician. At each examination, BP
evaluation. Persistent proteinuria was defined as urinary and heart rate were measured in sitting position in the
protein excretion $1 g/24 hours from at least three morning (8 to 9 a.m.), immediately before the ingestion
months without evidence of urinary tract infection or of the drug (“trough” BP), and serum creatinine and
overt heart failure (New York Heart Association Class electrolyte concentrations, other serum biochemical val-
III or more). A detailed description of the exclusion ues (uric acid, glucose, cholesterol, triglycerides, liver
enzymes, and bilirubin), and a complete blood countcriteria has been given elsewhere [9–11].
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were determined, as well as 24-hour urinary protein, not attend the Clinical Research Center and did not have
sodium, and urea excretion. The GFR was measured at their BP measured by either a standard sphygmomanom-
months 1, 3, and 6 after randomization and every six eter or an automatic device were not included in data
months thereafter. On each occasion, a fixed dose of analyses.
iohexol was injected immediately after the study drug
administration. To calculate the plasma clearance of io- Outcome measures
hexol, blood samples were taken immediately before the Outcome measures were DGFR, time to ESRF, and
injection of iohexol (time, 0 minute) and at predeter- 24-hour urinary protein excretion rate (measured by the
mined times thereafter: In patients with a baseline creati-
biuret precipitation method in all participating centers).nine clearance $45 mL/min/1.73 m2, blood samples were
To estimate the rate of GFR decline, a minimum of threetaken at 120, 150, 180, 210, and 240 minutes; in those
GFR measurements per patient (including baseline)with baseline creatinine clearance ,45 mL/min/1.73 m2,
were required.blood samples were taken at 120, 180, 240, 300, 360, 450,
and 600 minutes after the iohexol injection.
Statistical analysis
Blood pressure measurements Data were analyzed on an intention-to-treat basis. Di-
On the occasion of each GFR measurement, all pa- chotomous and polychotomous baseline characteristics
tients attending the Clinical Research Center for Rare were compared with Fisher’s exact test; continuous base-
Diseases “Aldo & Cele Dacco`” had their BP measured line characteristics were compared with the Wilcoxon
by a standard sphygmomanometer in the morning (8 to 9 rank-sum test. The primary analysis on the decline in
a.m.) shortly before study drug administration (“trough” GFR was carried out in patients who had three or more
BP). The trough value was the mean of three consecutive renal function determinations. A single-slope linear
measurements taken at the dominant arm two minutes model was used, and slopes were compared by Wilcoxon
apart with the patient in a sitting position. Immediately rank-sum test. For the analysis of the length of time to
after trough BP was measured, the cuff of an automized event end points, product-limit life-table distributions
device (Kolormon TM 7250; Kontron Instruments, Mun- were compared with the log-rank statistic. The Pearson
chen, Germany) was applied to the dominant arm, and
r correlation coefficient was estimated to summarize thethe BP was measured with the patient still in the sitting
relationship between two continuous variables. Multipleposition (“time 0” BP). Antihypertensive treatment, in-
regression and proportional hazards model were used including the study medication, was then administered.
order to analyze predictors of DGFR and time to ESRFThen additional BP measurements were taken by the
prospectively. Trough, 0 minute, 120 minutes, and moni-automatic device with the patient in the sitting position
tored BPs were included in the analyses. The analysesone minute before each blood sample collection during
were performed with Statistical Analysis System soft-each GFR measurement (0 to 240 minutes or 0 to 600
ware. A P value of less than 0.05 was considered tominutes for patients with baseline creatinine clearance $
indicate statistical significance. All statistical tests wereor ,45 mL/min/1.73 m2, respectively). The BP measured
by the automatic device and averaged throughout each two sided. Data are mean 6 SD or median and inter-
GFR measurement was defined as “monitored” BP. The quartile (IQ) range, unless otherwise stated.
measurement taken by the automatic device at 120 min- Before performing the previously mentioned analyses,
utes after treatment administration (“120-minute” BP) the agreement between the two methods of BP measure-
was selected among post-treatment measurements for ment (by standard sphygmomanometer or automatic de-
comparisons with trough, time 0, and monitored BP. vice) was assessed according to Bland and Altman [15].
Similar comparisons were done also for all the other post- Two repeated measures of systolic and diastolic BP were
treatment automatic measurements (data not shown). taken by both methods, in a random order, at the domi-
All BP values (trough, time 0, 120 minutes, and moni- nant arm of 42 subjects. The means of the two measure-
tored) were taken either at study entry (that is, at ran-
ments by each method in each individual patient weredomization, before any study treatment administration)
used for assessing agreement. A corrected standard devi-and throughout the entire study period (that is, during
ation of differences between methods was then calcu-the occasion of each GFR measurement) and were there-
lated [15]. Correlations (r 5 0.84, P 5 0.0001 vs. 0.77,fore referred to as “basal” or “follow-up” BPs, respec-
P 5 0.0001) and limits of agreements [standard minustively. Average follow-up BPs were the trough, time 0,
automatic measurements: 24.82 (226.22 to 16.58) vs.120 minutes, and monitored BPs taken at each GFR
1.23 (213.7 to 15.53) mm Hg] between the two methodsmeasurement (including baseline) and averaged through-
were calculated either for systolic and diastolic BP, re-out the entire study period.
Patients who entered the REIN study, but who did spectively.
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Table 1. Clinical characteristics at the time of randomization in the entire study group (Overall) and in patients with a baseline creatinine
clearance (CCr) , or $45 mL/min/1.73 m2 according to randomization to ramipril or conventional treatment
Overall CCr ,45 mL/min/1.73 m2 CCr $45 mL/min/1.73 m2
Ramipril Conventional Ramipril Conventional Ramipril Conventional
Variable mean6SDa (N 5 86) (N 5 77) (N 5 31) (N 5 34) (N 5 55) (N 5 43)
Demographics
Age years 51.7612.6 49.8614.9 53.0610.1 51.8615.2 51.0613.9 48.2614.6
Males number of patients (%) 68 (79%) 58 (75%) 24 (77%) 21 (62%) 44 (80%) 37 (86%)
Females number of patients (%) 18 (21%) 19 (25%) 7 (23%) 13 (38%) 11 (20%) 6 (14%)
Renal disease
Glomerular number of patients (%) 41 (48%) 30 (39%) 13 (42%) 11 (32%) 28 (51%) 19 (44%)
Interstitial, polycystic number of
patients (%) 8 (9%) 2 (3%) 4 (13%) 1 (3%) 4 (7%) 1 (2%)
Other, unknown number of patients
(%) 37 (43%) 45 (58%) 14 (45%) 22 (65%) 23 (42%) 23 (54%)
Renal function
GFR mL/min/1.73 m2 49.2620.0 44.5617.1 30.568.0 30.8611.5 59.8616.6 55.2612.6
Creatinine clearance mL/min/1.73 m2 52.5618.5 49.9617.9 31.368.3 33.368.8 64.4610.0 63.1610.8
Serum creatinine mg/dL 1.9960.81 2.1360.82 2.7660.75 2.7460.84 1.5660.42 1.6560.36
Urinary protein excretion g/dayb 3.2362.13 2.9961.97 3.4562.51 3.3461.67 3.1161.90 2.7162.16
Urinary urea excretion mmol/day 23.767.0 24.167.5 20.266.4 20.667.8 25.866.57 26.866.2
Urinary sodium excretion mmol/day 196.0678.7 189.1673.3 197.86102.4 186.5686.4 194.9662.4 191.2662.1
Arterial blood pressure
Systolic mm Hg 153.0617.2 151.9617.7 155.9618.6 153.0617.4 151.4616.2 151.1618.1
Diastolic mm Hg 94.7611.3 94.7612.3 94.8613.2 93.3612.0 94.7610.2 95.8612.6
Mean mm Hg 114.2612.2 113.7613.1 115.2613.6 113.2612.6 113.6611.5 114.2613.6
Lipids and potassium
Serum cholesterol mg/dL 250.5658.4 246.6649.1 258.8652.7 247.2655.5 246.2661.2 246.2644.1
Serum triglycerides mg/dL 208.76190.6 162.7694.5 216.96166.3 159.5687.2 204.26204.2 165.36100.7
Serum potassium mmol/L 4.5660.64 4.5060.57 4.5860.70 4.7460.54 4.4260.68 4.4660.47
a For no parameter differences between ramipril and conventional achieved the statistical significance (for categorical variables the P values were based on Fisher’s
exact test. The P values for continuous variables were based on the Wilcoxon test)
b Urinary protein excretion is the mean of the last two measurements before randomization
RESULTS creatinine clearance $45 mL/min/1.73 m2, and 147.5 6
13.2/90.3 6 7.4 versus 146.1 6 14.1/91.2 6 10.0 mm HgOverall, the present study included 163 of the 352
among patients with creatinine clearance ,45 mL/min/patients with proteinuric chronic nephropathies involved
1.73 m2. Of note, in both groups, ramipril and conven-in the REIN Study [9–11]. Of note, the proportion of
tional treatments achieved a “smooth” BP profile, with-patients with nephrotic range proteinuria (41 vs. 47%)
or arterial hypertension (88 vs. 84%) and on ramipril or out remarkable acute BP reductions shortly after treat-
conventional therapy (53 vs. 50%) in the present series ment administration (Fig. 1). Among patients with a
and in the whole REIN study group, respectively, was baseline creatinine clearance ,45 mL/min/1.73 m2, sys-
very well comparable. Main clinical and laboratory pa- tolic (ramipril, 144.0 6 12.1 mm Hg; conventional,
rameters in the overall study population and in the two 146.7 6 15.3 mm Hg) and diastolic (ramipril, 86.3 6 6.5
subgroups with baseline creatinine clearance ,45 or $45 mm Hg; conventional, 89.8 6 8.1 mm Hg) BP measure-
mL/min/1.73 m2 are listed in Table 1. A comparable ments averaged throughout the 600-minute monitoring
proportion of patients in the entire study group and period and at each time point were comparable in the
within the two subgroups was on ramipril or conven- two treatment groups (Fig. 1). In contrast, among pa-
tional treatment. Baseline characteristics of ramipril and tients with baseline creatinine clearance $45 mL/min/
conventionally treated patients were comparable in the en-
1.73 m2, systolic (ramipril, 140.9 6 13.7 mm Hg; conven-
tire study group and within the two subgroups (Table 1).
tional, 147.4 6 14.1 mm Hg) and diastolic (ramipril,The course of systolic/diastolic BP monitored during
85.2 6 1.5 mm Hg; conventional, 90.8 6 6.1 mm Hg) BPsthe GFR measurements in ramipril or conventionally
averaged throughout the 600-minute monitoring periodtreated patients with baseline creatinine clearance ,45
and at each time point tended to be higher in the conven-or $45 mL/min/1.73 m2, averaged throughout the entire
tional than in the ramipril group (Fig. 1). However, de-study period, is shown in Figure 1. The corresponding
spite the different response with regards to BP reduction,trough systolic/diastolic BP values averaged during the
the two groups of patients with baseline creatinine clear-study period in the ramipril and conventional treatment
ance ,45 or $45 mL/min/1.73 m2 had a virtually identicalgroups were 142.8 6 14.9/88.8 6 8.7 versus 145.2 6 12.8/
91.1 6 8.4 mm Hg, respectively, among patients with pattern of response to ramipril as compared with conven-
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Fig. 1. Course of systolic and diastolic blood pressure (BP) monitored through glomerular filtration rate (GFR) measurements in 98 patients with
baseline creatinine clearance $45/mL/min/1.73 m2 (A) and in 65 patients with baseline creatinine clearance ,45/mL/min/1.73 m2 (B) on ramipril
(j) or conventional (h) treatment. BP values are means 6 SD of measurements taken at each time point during the entire study period, including
baseline. Corresponding follow-up trough systolic and diastolic BPs are given in the text.
tional treatment, in terms of reduction in proteinuria, 120-minute diastolic BP did not correlate with the rate
of GFR decline in both study groups. Follow-up diastolicDGFR, and progression to ESRF (Fig. 2).
Correlations between trough, 0-minute, or 120-minute BP values were always predictive of GFR decline, re-
gardless of the timing of measurement.systolic/diastolic BP values and monitored systolic/dia-
stolic BP values at baseline and follow-up are shown in Correlations between baseline trough, 0-minute, 120-
minute, and monitored systolic/diastolic BP values andTable 2. Of note, either at baseline or follow-up and
regardless of the level of baseline creatinine clearance, DGFR in ramipril and conventionally treated patients
are given in Table 5. Of note, as compared with theboth trough and 120-minute BPs correlated very well
with monitored BP measurements, with correlation coef- correlations in the study group as a whole, the correla-
tions between all the parameters considered (either atficients that were remarkably higher for systolic than for
diastolic BP (Table 2). baseline and on follow-up) and DGFR remarkably im-
proved in the ramipril-treated patients and, in contrast,Correlations of baseline or follow-up trough, 0-minute,
120-minute, and monitored systolic/diastolic BPs with weakened in the conventionally treated patients. Of in-
terest, among different baseline measurements, onlyDGFR are given in Tables 3 and 4. Of note, trough,
0-minute, 120-minute, and monitored systolic BPs corre- trough systolic BP retained a statistically significant cor-
relation with DGFR in the conventional treatment grouplated with DGFR better than the corresponding diastolic
BPs, particularly at baseline and in the subgroup of pa- (Table 5).
Results of multivariate regression analyses, also in-tients with a baseline creatinine clearance ,45 mL/min/
1.73 m2. However, among the different parameters con- cluding age, GFR, cholesterol, triglycerides and the 24-
hour urinary protein excretion rate, between the inde-sidered, trough and 0-minute systolic BPs were the only
parameters that significantly correlated with DGFR ei- pendent (baseline and follow-up trough, 0-min, 120-min,
and monitored diastolic BP) covariates and the risk ofther at baseline or follow-up, in the entire study group
and in both subgroups with baseline creatinine clear- progression to ESRF are shown in Table 6. The analyses
were not performed in patients with a creatinine clear-ance , or $45 mL/min 1.73 m2. In contrast, the 120-
minute baseline and follow-up systolic BP measurements ance $45 mL/min/1.73 m2, since only one event occurred
in this subgroup. Of note, no baseline measurement ofcorrelated with the GFR decline in patients with a creati-
nine clearance ,45 mL/min 1.73 m2, but not in those systolic or diastolic BP was significantly associated with
the risk of ESRF. In contrast, the association betweenwith less severe renal insufficiency. Of note, the baseline
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Table 2. Pearson correlation coefficients of trough, 0 minute, and
120 minutes of systolic/diastolic blood pressure with monitored
systolic/diastolic blood pressure at baseline and on follow-up in the
entire study group, and in the two subgroups of patients with baseline
creatinine clearance $ or ,45 mL/min/1.73 m2
Systolic blood Diastolic blood
pressure pressure
Baseline Follow-up Baseline Follow-up
Trough
$45 mL/min/1.73 m2 0.86 0.91 0.73 0.86
,45 mL/min/1.73 m2 0.84 0.86 0.77 0.77
Overall 0.85 0.87 0.75 0.80
0 min
$45 mL/min/1.73 m2 0.85 0.94 0.72 0.89
,45 mL/min/1.73 m2 0.82 0.88 0.78 0.82
Overall 0.83 0.90 0.75 0.85
120 min
$45 mL/min/1.73 m2 0.86 0.94 0.81 0.89
,45 mL/min/1.73 m2 0.85 0.95 0.84 0.89
Overall 0.86 0.95 0.83 0.89
P 5 0.0001 for all the correlations considered.
Table 3. Correlations of baseline and follow-up trough, 0 minute,
120 minutes and monitored systolic blood pressure measurements
with DGFR in the whole study group and in the two subgroups with
baseline creatinine clearance , or $ 45 mL/min/1.73 m2
CCr ,45 mL/ CCr $45 mL/
Overall min/1.73 m2 min/1.73 m2
r P value r P value r P value
Baseline
Trough 20.34 0.0001 20.35 0.0009 20.32 0.01
0 min 20.27 0.001 20.23 0.03 20.37 0.01
120 min 20.23 0.006 20.26 0.009 20.06 0.69
Monitored 20.32 0.0001 20.33 0.0008 20.25 0.09
Fig. 2. Percent changes (mean 6 SEM) in proteinuria versus baseline Follow-up
(A) and DGFR (B) and incidence of ESRF (C) on follow-up in patients Trough 20.39 0.0001 20.36 0.0002 20.41 0.005
with creatinine clearance $45 mL/min/1.73 m2 (right panels) or with 0 min 20.39 0.0001 20.29 0.005 20.51 0.0001
creatinine clearance ,45 mL/min/1.73 m2 (left panels) on ramipril (j) 120 min 20.35 0.0001 20.35 0.0003 20.29 0.05
or conventional (h) treatment. Monitored 20.41 0.0001 20.39 0.0001 20.42 0.003
r 5 Pearson correlation coefficient.
follow-up systolic or diastolic BP and risk of ESRF was
highly significant for any of the considered measure-
Table 4. Correlations of baseline and follow-up trough, 0 minute,ments either in the entire study group or in the subgroup
120 minutes and monitored diastolic blood pressures with DGFR
of patients with creatinine clearance ,45 mL/min/1.73 in the whole study group and in the two subgroups with baseline
creatinine clearance , or $ 45 mL/min/1.73 m2m2 (Table 6).
Multivariate regression analyses, including all of the CCr ,45 mL/ CCr $45 mL/
Overall min/1.73 m2 min/1.73 m2parameters considered in the entire study group, be-
tween independent (baseline and follow-up trough, r P value r P value r P value
0-min, 120-min, and monitored diastolic BP) covariates Baseline
and risk of progression to ESRF were not possible in Trough 20.20 0.02 20.26 0.02 20.12 0.35
0 min 20.25 0.003 20.19 0.08 20.38 0.004ramipril treated patients because the number of events
120 min 20.15 0.08 20.18 0.10 20.10 0.44
was too limited. Of interest, despite the smaller sample Monitored 20.24 0.003 20.26 0.01 20.23 0.08
Follow-upsize, trough follow-up (but not baseline) systolic and
Trough 20.38 0.0001 20.43 0.0001 20.27 0.03diastolic BP values retained an independent predictive
0 min 20.32 0.0001 20.24 0.03 20.42 0.0008
value of ESRF even in conventionally treated patients 120 min 20.31 0.0002 20.30 0.004 20.28 0.03
Monitored 20.36 0.0001 20.36 0.0005 20.34 0.008[systolic RR (95% CI) 5 1.07 (1.01 to 1.13), P 5 0.02;
r 5 Pearson correlation coefficient.diastolic RR (95% CI) 5 1.49 (1.10 to 2.02), P 5 0.01].
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Table 5. Correlations of baseline and follow-up trough, 0 minute, 120 minutes and monitored systolic or diastolic blood pressures with
DGFR in the ramipril and conventional treatment groups
Systolic blood pressure Diastolic blood pressure
Ramipril Conventional Ramipril Conventional
r P value r P value r P value r P value
Baseline
Trough 20.43 0.0001 20.28 0.02 20.31 0.006 20.12 0.34
0 min 20.40 0.0003 20.16 0.20 20.37 0.001 20.12 0.33
120 min 20.36 0.001 20.13 0.28 20.18 0.10 20.11 0.37
Monitored 20.44 0.0001 20.23 0.06 20.31 0.006 20.16 0.18
Follow-up
Trough 20.49 0.0001 20.26 0.03 20.44 0.0001 20.28 0.02
0 min 20.45 0.0001 20.31 0.01 20.32 0.004 20.28 0.02
120 min 20.39 0.0004 20.29 0.02 20.22 0.045 20.32 0.007
Monitored 20.37 0.0001 20.33 0.007 20.32 0.003 20.33 0.006
r 5 Pearson correlation coefficient.
Table 6. Multivariate analysis of baseline and follow-up trough, 0 minute, 120 minutes and monitored systolic or diastolic blood pressure,
and incidence of ESRF in the entire study group (Overall) and in the subgroup of patients with baseline creatinine
clearance , 45 mL/min/1.73 m2
Systolic blood pressure Diastolic blood pressure
Overall CCr ,45 mL/min/1.73 m2 Overall CCr ,45 mL/min/1.73 m2
Variable 95% CI P value 95% CI P value 95% CI P value 95% CI P value
Baseline
Trough 1.00 (0.97–1.03) 0.95 1.00 (0.97–1.04) 0.86 0.98 (0.94–1.01) 0.21 0.98 (0.95–1.02) 0.38
0 min 0.99 (0.96–1.02) 0.50 0.99 (0.96–1.01) 0.30 0.98 (0.95–1.02) 0.32 0.98 (0.95–1.01) 0.24
120 min 1.01 (0.98–1.04) 0.71 1.01 (0.98–1.04) 0.62 0.99 (0.95–1.03) 0.72 1.00 (0.96–1.04) 1.00
Monitored 1.02 (0.99–1.06) 0.16 1.02 (0.99–1.06) 0.17 1.01 (0.97–1.07) 0.58 1.02 (0.97–1.07) 0.50
Follow-up
Trough 1.07 (1.02–1.11) 0.003 1.07 (1.02–1.12) 0.004 1.22 (1.09–1.38) 0.001 1.21 (1.07–1.37) 0.002
0 min 1.04 (1.01–1.07) 0.009 1.04 (1.01–1.08) 0.01 1.13 (1.04–1.22) 0.002 1.14 (1.04–1.25) 0.007
120 min 1.08 (1.04–1.13) 0.0002 1.08 (1.03–1.12) 0.0007 1.25 (1.10–1.42) 0.0006 1.25 (1.09–1.44) 0.001
Monitored 1.49 (1.14–1.94) 0.004 1.08 (1.03–1.12) 0.0009 1.25 (1.09–1.43) 0.001 1.23 (1.07–1.40) 0.003
Abbreviation is: 95% CI, 95% Confidence Interval.
DISCUSSION predictive parameter. Indeed, in patients with a creati-
nine clearance $45 mL/min/1.73 m2, the 120-minute sys-In our study, regardless of the severity of basal renal
tolic BP was the only parameter that did not correlateinsufficiency, either baseline and follow-up trough, 0-min-
with the decline in GFR at either baseline or follow-up.ute, and 120-minute systolic or diastolic BP values corre-
In parallel, baseline 120-minute diastolic BP was the onlylated to a similar extent with its corresponding monitored
parameter that never correlated with GFR decline in allBP measurement. However, as compared to the 120-
patients, regardless of the level of renal insufficiency. Inminute BP, the trough and 0-minute measurements—
contrast, both trough and time 0 systolic and diastolicthat is, morning pretreatment BPs—were stronger pre-
BP measurements had a predictive value that was quitedictors of progression, and their predictability was re-
close to that of the monitored BP. Of note, finding thatmarkably good in particular in the ramipril-treated
the predictive value of trough and time 0 BP values waspatients.
virtually identical demonstrates that the reliability ofOverall, correlation analyses with DGFR found that
these two parameters is directly dependent on the timingsystolic was more reliable than diastolic BP in predicting
(shortly before treatment administration), rather thandisease progression. Moreover, trough and time-0 sys-
on the modality (by a standard sphygmomanometer fortolic BP measurements were the only parameters that
trough and by an automatic device for time 0 BP) orsignificantly correlated with GFR decline, both at base-
the number (3 for trough and only 1 for time 0 BP) ofline and on follow-up, in patients with more severe renal
measurements.insufficiency and in those with more preserved renal
The predictive value of trough and time 0 systolicfunction. In contrast, BP measured 120 minutes after
effective therapy was administered was clearly the least and diastolic BP measures was further corroborated by
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results of multivariate analyses evaluating the relation- the predictive value of proteinuria was remarkably de-
ships between the BP values and risk of progression to creased (or fully blunted) because of the effect of ACE
ESRF. In particular, these analyses clearly documented inhibition treatment on glomerular hemodynamics and
that, in addition to predicting a faster GFR decline, barrier size–selectivity [18, 19]. Indeed, this effect, by
higher follow-up trough and time 0 BPs were also sig- limiting protein ultrafiltration (and proteinuria), pre-
nificant and independent predictors of an increased risk vents the sequence of events triggered by enhanced pro-
of progression to ESRF. The predictive value was evi- tein traffic that eventually contributes to progressive
dent both in the study group as a whole and in the structural damage and renal dysfunction [1]. Thus, when
subgroup of patients at the highest risk of progression the predictive value of proteinuria is blunted, arterial BP
because of a more severe renal insufficiency at study becomes the most important predictor of progression.
entry. These data clearly show that trough and time 0 These findings suggest that in the day by day manage-
BP measurements can be taken as reliable surrogates ment of patients with progressive chronic nephropathies,
for monitored BP. In other words, BP measured shortly targeting the treatment to reach an optimal BP control
before treatment administration, regardless of the is extremely important in maximizing the renoprotection
adopted procedure, is a reliable and practical indicator conferred by chronic ACE inhibitor therapy. Actually,
of overall BP control, and may serve to evaluate the
this approach can be remarkably effective in type 1 dia-
patient’s response to antihypertensive treatment while
betics with overt nephropathy (Lewis E, Clinical Ne-avoiding the need of time- and cost-consuming pro-
phrology Symposium: Diabetes, the Kidney and More;longed BP monitoring (which, however, remains the gold
32nd Annual Meeting of the American Society of Ne-standard for BP measurement, since it more tightly re-
phrology, Miami, 1999).flects the overall BP to which target organs are exposed
Another important finding of this study is that in allduring the day). The reliability of this parameter is fur-
patients, even in those with more severe renal insuffi-ther confirmed by evidence that in patients with progres-
ciency, ramipril induced no acute reductions in arterialsive chronic nephropathies and different degrees of renal
BP shortly after its administration. This may explain whydysfunction, the trough BP predicts disease outcome in
it was so well tolerated and none of the patients enrolledthe long term at least as precisely as the monitored BP
in the REIN study required treatment withdrawal be-measurements. In contrast, single measurements taken
cause of symptomatic hypotension [9–11].120 minutes after treatment administration are not as
In conclusion, to our knowledge this is the first studyreliable, to the extent that they predicted the risk of
ESRF, but not the GFR decline in the long term. The that prospectively analyzes the predictive value of differ-
lower predictive value of post-treatment as compared ent methods of BP measurement in patients with chronic
with pretreatment measurements may be due to the progressive nephropathies. Within the limits of a study
changes in BP that may occur at different times after that was not formally designed to explore the reliability
treatment administration, in correspondence with the of different BP measurements and that may have the
peak effect of different antihypertensive drugs. On the drawbacks of post hoc analyses, the study findings can
other hand, discovering that both the trough and 0 min- be taken to conclude the following: (1) BP measured just
ute measurements were better predictors of outcome before the administration of antihypertensive therapy,
than the 120-minute values, and that their predictive regardless of the measurement procedure, is a simple
values were comparable ruled out the possibility of a and precise indicator of daily BP control that may serve
confounding effect of different technical procedures. to guide antihypertensive therapy as well as predict dis-
The failure to detect a predictive value for arterial BP ease outcome; (2) since systolic BP, in comparison to
when analyses were restricted to conventionally treated
diastolic BP, is an even stronger predictor of outcome,
patients is consistent with previous evidence that in pro-
antihypertensive therapy should be primarily aimed atteinuric chronic nephropathies, among a series of clinical
normalizing systolic hypertension, even when diastolicand laboratory parameters, arterial BP is a relatively
BP is within ideal ranges; (3) single BP measurementsweak predictor of outcome, particularly as compared
taken shortly after treatment administration may notwith proteinuria [16, 17]. Conceivably, on conventional
reliably reflect the real level of daily BP control andtreatment, patients with more proteinuria tend to have
should not be used for monitoring the BP response toa faster progression even independently of the actual
antihypertensive treatment either in routine clinicallevels of BP control. In contrast, when patients are on
practice or in prospective controlled trials; (4) carefuleffective antiproteinuric treatment—for instance, as in
BP monitoring and effective antihypertensive treatmentthe present study, by an ACE inhibitor—the predictive
are extremely important in maximizing renoprotection,value of proteinuria is almost entirely blunted, and arte-
even in patients who are already on chronic ACE inhibi-rial BP becomes the strongest predictor of progression. A
suggested explanation is that in ramipril-treated patients, tor therapy.
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